Compare CFLT & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CFLT | DVA |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 8.2B |
| IPO Year | 2021 | 1995 |
| Metric | CFLT | DVA |
|---|---|---|
| Price | $30.41 | $112.68 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 32 | 4 |
| Target Price | $29.93 | ★ $145.00 |
| AVG Volume (30 Days) | ★ 14.7M | 743.4K |
| Earning Date | 02-10-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.63 |
| EPS | N/A | ★ 9.76 |
| Revenue | $1,113,149,000.00 | ★ $13,317,965,000.00 |
| Revenue This Year | $22.76 | $6.50 |
| Revenue Next Year | $16.57 | $2.97 |
| P/E Ratio | ★ N/A | $11.37 |
| Revenue Growth | ★ 21.57 | 5.14 |
| 52 Week Low | $15.64 | $110.33 |
| 52 Week High | $37.90 | $179.60 |
| Indicator | CFLT | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 77.39 | 38.63 |
| Support Level | $30.09 | $110.33 |
| Resistance Level | $30.33 | $115.82 |
| Average True Range (ATR) | 0.12 | 2.31 |
| MACD | -0.24 | -0.13 |
| Stochastic Oscillator | 97.87 | 26.30 |
Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.